acquired
Stage
2
Investors
About
XERIS Pharmaceuticals is a specialty biopharmaceutical company developing improved injectable therapeutics and proprietary formulation technologies (XeriSol and XeriJect) for subcutaneous and intradermal delivery of peptides, proteins, antibodies and small molecules. Its formulations enable highly concentrated, non‑aqueous, ready‑to‑use products for use with auto‑injectors, pens and pumps, offering reduced injection volumes and room‑temperature stability.
Explore XERIS Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.